BioLineRx Ltd.
BLRX
$4.24
-$0.33-7.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 836.64% | 77.05% | 63.66% | 102.61% | 94.28% |
| Total Depreciation and Amortization | -81.61% | 174.96% | 280.09% | 140.40% | 246.33% |
| Total Amortization of Deferred Charges | -- | 1,157.63% | -- | -- | -- |
| Total Other Non-Cash Items | -128.02% | -317.56% | -129.77% | -152.90% | -197.95% |
| Change in Net Operating Assets | 95.24% | -102.79% | -394.01% | -659.92% | -4,045.05% |
| Cash from Operations | 81.64% | -272.51% | 0.77% | -17.01% | -76.01% |
| Capital Expenditure | -- | 137.50% | 100.00% | 59.70% | 0.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -148.91% | 154.72% | 148.29% | -177.17% | 150.51% |
| Cash from Investing | -149.00% | 154.70% | 148.35% | -177.88% | 151.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -39.49% | -1,302.43% | -10.19% | -578.36% | -1,724.49% |
| Issuance of Common Stock | -- | -12.77% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,157.05% | -109.45% | -134.81% | 17,920.15% | -1,724.49% |
| Foreign Exchange rate Adjustments | -260.78% | -15.63% | 212.50% | -10.57% | 152.04% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -180.69% | 146.08% | 66.89% | 250.00% | 214.07% |